Dietary Supplement
TA-65
TA-65 is a dietary supplement with 3 clinical trials. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DIETARY SUPPLEMENT
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph not_applicable
2
67%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
2(66.7%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Completed1
Not yet recruiting1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 1
Trials by Phase
Phase 11 (33.3%)
N/A2 (66.7%)
Trials by Status
completed133%
not_yet_recruiting133%
terminated133%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingnot_applicable
TA-65 and Aging Associated Microvascular Dysfunction
NCT05598359
completednot_applicable
Effects of TA-65, a Telomerase Activator on Metabolic Syndrome
NCT02531334
terminatedphase_1
The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome
NCT01753674
Clinical Trials (3)
Showing 3 of 3 trials
NCT05598359Not Applicable
TA-65 and Aging Associated Microvascular Dysfunction
NCT02531334Not Applicable
Effects of TA-65, a Telomerase Activator on Metabolic Syndrome
NCT01753674Phase 1
The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome
All 3 trials loaded
Drug Details
- Intervention Type
- DIETARY SUPPLEMENT
- Total Trials
- 3